Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
Worth Seeing!
Raymond Moses: Unleashing the Financial Potential of Billions!
Biocon is currently trading at Rs. 270.00, up by 1.55 points or 0.58% from its previous closing of Rs. 268.45 on the BSE.
The scrip opened at Rs. 270.00 and has touched a high and low of Rs. 274.00 and Rs. 268.00 respectively. So far 6519 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 390.05 on 27-Apr-2011 and a 52 week low of Rs. 240.10 on 20-Dec-2011.
Last one week high and low of the scrip stood at Rs. 287.65 and Rs. 261.50 respectively. The current market cap of the company is Rs. 5401.00 crore.
The promoters holding in the company stood at 60.91% while Institutions and Non-Institutions held 13.95% and 25.13% respectively.
Biocon, Asia's premier biotechnology company, is all set to tap the US markets as the company is planning to sell its anti-cholesterol drug- atorvastatin- in the US from Financial Year (FY) 2013.
The US market for atorvastatin has recently opened up for generic companies. Further, the company plans to follow Watson and Ranbaxy, which have already launched their products in the markets and are currently under six months exclusivity phase.
The company has seen a significant growth in branded atorvastatin (Statix) as well as sales of active pharmaceutical ingredients (API). Similarly, Biocon is also planning to tap the European market, where it is currently selling atorvastatin with its partners. Biocon has major presence in emerging and unregulated markets with its branded atorvastatin (Statix).
Biocon is Asia’s leading R&D based Biotechnology Company. It produces anti-diabetic agents like Acarbose, Pioglitazone, Repaglinides and Rosiglitazone. In the biological segment it produces Insulin, Erythropoietin (EPO), Filgrastim (GCSF), Streptokinase and Monoclonal Antibodies. The drug major also produces mycophenolate mofetil, sirolimus and tacrolimus.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1849.05 |
| Dr. Reddys Lab | 1274.25 |
| Cipla | 1553.20 |
| Lupin | 2184.00 |
| Zydus Lifesciences | 1001.85 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
